Italian Drugmaker Chiesi to Acquire KalVista for $1.9 Billion
Chiesi's $1.9B acquisition of KalVista signals a strategic expansion in rare immunology, with implications for rare disease treatment supply and commercialization.
Read insighttherapeutic areas
Rare Diseases
Rare Diseases is monitored by UniPharma because shifts in demand, reimbursement, regulation, competition, or supply priorities can reshape procurement and launch planning.
Related insights
Latest articles on Rare Diseases
April 29, 2026
Chiesi Group Grows Again in Rare Disease With $1.9B KalVista Acquisition
Chiesi acquires KalVista for $1.9B, adding oral HAE drug Ekterly. The deal boosts rare disease portfolio with a differentiated on-demand treatment.
Read insightApril 29, 2026
Chiesi's $1.9bn KalVista Acquisition Bolsters Rare Disease Portfolio with First Oral HAE Therapy
Chiesi acquires KalVista for $1.9bn, securing first oral HAE therapy Ekterly. The deal transforms HAE attack treatment, shifting from injectables to oral, with implications for supply chain, hospital formularies, and market access in UK and EU.
Read insightApril 29, 2026
Chiesi's $1.9B Acquisition of KalVista Boosts Rare Disease Portfolio with EKTERLY (sebetralstat) for HAE
Chiesi Group acquires KalVista for $1.9B, gaining oral HAE drug EKTERLY, expanding US presence and targeting €6B revenue by 2030.
Read insightApril 29, 2026
Chiesi’s $1.9B KalVista Buyout Bolsters Rare Disease Pipeline
Chiesi's $1.9 billion acquisition of KalVista strengthens its rare disease pipeline and signals consolidation in the orphan drug space.
Read insightApril 29, 2026
Chiesi Acquires KalVista for $1.9bn, Adding Oral HAE Drug Sebetralstat
Chiesi’s $1.9bn acquisition of KalVista brings sebetralstat, the first oral on-demand therapy for hereditary angioedema, expanding its rare disease pipeline.
Read insightApril 29, 2026
Chiesi Acquires KalVista for $1.9B, Adding Oral HAE Therapy Ekterly
Chiesi acquires KalVista for $1.9B, gaining oral HAE therapy Ekterly. The deal reshapes the rare disease competitive landscape and expands Chiesi's U.S. presence.
Read insightApril 29, 2026
Chiesi Group Acquires KalVista for $1.9 Billion to Boost Rare Disease Portfolio
Chiesi's $1.9 billion acquisition of KalVista strengthens its rare disease pipeline, signaling continued consolidation in the space.
Read insightApril 29, 2026
Chiesi Acquires KalVista for $1.9B to Strengthen Rare Disease Portfolio
Chiesi Group buys KalVista for $1.9B, adding oral HAE drug EKTERLY (sebetralstat) to rare disease portfolio. Deal expected to close Q3 2026.
Read insightApril 29, 2026
Chiesi's $1.9 Billion KalVista Deal Puts Rare Diseases First
Chiesi's $1.9B cash buyout of KalVista adds oral HAE drug EKTERLY and boosts US rare-disease footprint as it targets €6B revenue by 2030.
Read insightApril 29, 2026
Chiesi Group Acquires KalVista Pharmaceuticals, Expanding Rare Disease Portfolio with Oral HAE Therapy
Chiesi's $1.9bn acquisition of KalVista brings the first oral on-demand HAE therapy, sebetralstat, strengthening its rare disease portfolio and US commercial infrastructure.
Read insightApril 29, 2026
From constraint to catalyst: innovation in rare disease clinical development
Rare disease development forces innovation in trial design and evidence generation. FDA flexibility on single pivotal trials reflects a shift with implications for manufacturers entering this space.
Read insightApril 29, 2026
AI is finally cracking rare disease diagnosis and that could save years of searching
EvORanker identifies the correct disease-causing gene as top candidate in nearly 70% of cases, potentially cutting years off rare disease diagnosis.
Read insightApril 28, 2026
Rocket sells priority review voucher for $180M after Kresladi gene therapy approval
Rocket Pharmaceuticals sold a rare pediatric disease priority review voucher for $180 million after FDA approval of its gene therapy Kresladi.
Read insightApril 27, 2026
Intellia's CRISPR Therapy Shows Efficacy in HAE Phase 3 Trial
A single dose of lonvo-z reduced swelling attacks in HAE patients, positioning it as the second approved CRISPR medicine and first in vivo treatment. What this means for market access.
Read insightApril 27, 2026
Intellia's CRISPR Treatment Reduces Swelling Attacks in Hereditary Angioedema Trial
Intellia's CRISPR-based therapy for hereditary angioedema cut attacks by 87% in a Phase 3 trial, paving the way for FDA approval as the first in vivo gene editing medicine.
Read insightApril 27, 2026
Breaking Barriers in Rare Disease Clinical Trials: Lessons from the VALOR Trial
Priovant's VALOR trial in dermatomyositis offers lessons on study design, patient retention, and sponsor-vendor collaboration for rare disease phase 3 trials.
Read insight